1. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:22 PM ET 06/15/2022

      Wednesday's session saw 269 companies set new 52-week lows. Here are all the stocks that set new 52-week lows on Wednesday: Be sure to monitor Benzinga for the news traders need!

  2. Show article details.

    InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

    GlobeNewswire – 8:00 AM ET 06/09/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention System for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard™ Embolic Prevention Stent System, from LINC 2022, which was held June 6-9.

  3. Show article details.

    5 Stocks To Watch For June 6, 2022

    Benzinga – 4:09 AM ET 06/06/2022

    Some of the stocks that may grab investor focus today are: Check out our premarket coverage here

  4. Show article details.

    BRIEF-InspireMD Inc Files For Mixed Shelf Of Up To $150 Million

    Reuters – 4:19 PM ET 06/03/2022

    InspireMD Inc (NSPR): * INSPIREMD INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Further company coverage:

  5. Show article details.

    InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

    GlobeNewswire – 8:00 AM ET 06/02/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention System for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course 2022, which is being held June 6-9 in Leipzig, Germany.

  6. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:28 PM ET 05/11/2022

      On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  7. Show article details.

    Recap: InspireMD Q1 Earnings

    Benzinga – 8:00 AM ET 05/10/2022

      InspireMD reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:30 AM. Here's what investors need to know about the announcement. InspireMD beat estimated earnings by 28.75%, reporting an EPS of $-0.57 versus an estimate of $-0.8. Revenue was up $177.00 thousand from the same period last year.

  8. Show article details.

    BRIEF-Inspiremd Reports First Quarter 2022 Financial Results And Business Update

    Reuters – 7:31 AM ET 05/10/2022

    InspireMD Inc (NSPR): * INSPIREMD REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.57. * Q1 REVENUE ROSE 17.6 PERCENT TO $1.183 MILLION Source text for Eikon: Further company coverage:

  9. Show article details.

    InspireMD Reports First Quarter 2022 Financial Results and Business Update

    GlobeNewswire – 7:30 AM ET 05/10/2022

               - 20% growth in CGuard™ revenue Year-over-Year -            - C-Guardian FDA IDE Trial Completes First European Enrollment -            - Held Key Opinion Leader Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages -            - European logistics hub established with BOMI Group –for direct market access as well as establishing...

  10. Show article details.

    Earnings Scheduled For May 10, 2022

    Benzinga – 5:18 AM ET 05/10/2022

      MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. ** Target Hospitality is projected to report earnings for its first quarter. ** Hudson Global is projected to report earnings for its first quarter. ** Maiden Hldgs is estimated to report earnings for its first quarter. ** WhiteHorse Finance is likely to report earnings for its first quarter.

  11. Show article details.

    InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

    GlobeNewswire – 7:30 AM ET 04/28/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens.

  12. Show article details.

    InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio

    GlobeNewswire – 4:05 PM ET 03/16/2022

    InspireMD, Inc. (NSPR), a global developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leader webinar on its CGuard Stent Platform and it’s MicroNet™ portfolio on Tuesday, March 22, 2022 at 2 p.m. Eastern Time.

  13. Show article details.

    InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

    GlobeNewswire – 7:30 AM ET 03/08/2022

    - CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Authority - - CGuard Included as Carotid Stent Treatment Option in National Institute of Neurological Disorders and Stroke Sponsored CREST-2 Trial...

  14. Show article details.

    InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

    GlobeNewswire – 7:00 AM ET 02/28/2022

    - CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke and actively engaged at more than 140 study locations - TEL AVIV, Israel, Feb. 28, 2022 -- InspireMD, Inc. (NSPR), a global developer of the CGuard™ Embolic Prevention Stent System device ...

  15. Show article details.

    InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

    GlobeNewswire – 4:30 PM ET 02/22/2022

    -Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announces it will report fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, before the market opens.

  16. Show article details.

    InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

    GlobeNewswire – 8:00 AM ET 02/15/2022

    InspireMD, Inc. (NSPR), a global developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Company’s Scientific Advisory Board.

  17. Show article details.

    InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

    GlobeNewswire – 8:00 AM ET 01/27/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System for prevention of stroke caused by Carotid Artery Disease, today announced that Marvin Slosman, Chief Executive Officer, is scheduled to present at the IAGS’ Biennial Scientific Meeting being held from January 31 – February 3, 2022 in Punta Cana, Dominican Republic.

  18. Show article details.

    InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

    GlobeNewswire – 8:11 AM ET 01/18/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System for prevention of stroke caused by Carotid Artery Disease, today announced that a live case demonstration featuring CGuard™ EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022.

Page:

Today's and Upcoming Events

  • Aug
    08

    NSPR to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    10

    NSPR announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.